Author:
Schaefer Robin,Schmidt Heather-Marie A,Ravasi Giovanni,Mozalevskis Antons,Rewari Bharat B,Lule Frank,Yeboue Kouadio,Brink Anne,Mangadan Konath Nabeel,Sharma Mukta,Seguy Nicole,Hermez Joumana,Alaama Ahmed S,Ishikawa Naoko,Dongmo Nguimfack Boniface,Low-Beer Daniel,Baggaley Rachel,Dalal Shona
Funder
Bill & Melinda Gates Foundation
World Health Organization
Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference21 articles.
1. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force;Chou;JAMA,2019
2. FDA paves the way for pre-exposure HIV prophylaxis;Holmes;Lancet,2012
3. Landovitz R, Donnell D, Clement M, et al. HPTN083 interim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW). 23rd International AIDS Conference; virtual; July 6–10, 2020 (abstr 10750).
4. Are 2 million bottles of PrEP an empty gesture?;Lancet HIV,2019
5. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017;Sullivan;Ann Epidemiol,2018
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献